REG - Arecor Therapeutics - Posting of 2023 Annual Report and Notice of AGM

Arecor TherapeuticsAnnouncement

31/05/2024 16:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240531:nRSe6699Qa&default-theme=true

RNS Number : 6699Q  Arecor Therapeutics PLC  31 May 2024

POSTING OF ARECOR 2023 ANNUAL REPORT AND NOTICE OF AGM

 

Cambridge, UK, 31 May 2024. Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical company advancing today's therapies to enable healthier
lives, announces that it has today published and posted to shareholders the
Annual Report and Accounts for the year ended 31 December 2023 and Notice of
the Annual General Meeting ("AGM") which will be held at the offices of
Covington & Burling LLP, 22 Bishopsgate, London EC2N 4BQ, on 28 June 2024
at 12.00 p.m. (BST).

 

The Annual Report and Accounts and notice of AGM are also available to view
on, and download from, the Company's website at
https://arecor.com/investor-centre/shareholder-information/
(https://arecor.com/investor-centre/shareholder-information/)

 

-ENDS-

 

For more information, please contact:

 Arecor Therapeutics plc                           www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer          Tel: +44 (0) 1223 426060

                                                   Email: info@arecor.com

 Susan Lowther, Chief Financial Officer            Tel: +44 (0) 1223 426060

                                                   Email: info@arecor.com

 Panmure Gordon (UK) Limited (NOMAD and Broker)    Tel: +44 (0) 20 7886 2500

 Freddy Crossley, Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 WG Partners LLP (Financial Advisor)               Tel: +44 (0)203 705 9321

 Nigel Barnes, Satheesh Nadarajah

 David Wilson, Claes Spang

 ICR Consilium
 Chris Gardner, David Daley, Lindsey Neville       Tel: +44 (0) 20 3709 5700

                                                   Email: arecor@consilium-comms.com

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other indications, as well
as working with leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat™ platform is supported by an extensive
patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOABGGDUBGXDGSB